Fulcrum Therapeutics (FULC) PT Raised to $16 at Leerink Partners
Tweet Send to a Friend
Leerink Partners analyst Joseph P. Schwartz raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $16.00 (from $12.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
